Pioneer Pharmaceuticals has released final data on the trial of new crown male subjects with psyrus

On January 7th Pioneer Pharmaceuticals announced that the final trial data from its study of new crown male subjects for psyruline therapy in Brazil had been released.
results showed that psyruamine significantly inhibited the conversion from mild to severe in patients with neo-corona, and that short-term medication (15 days) was safe.
The clinical trial of the new crown for the treatment of psyruamine is a randomized, double-blind and placebo-controlled clinical trial designed to explore the effectiveness of psyruamine in treating new crown patients, accelerate the rate of positive-to-negative patients and prevent the transition from mild to severe by inhibiting viral replication and reproduction.
main endpoints included the percentage of subjects admitted to hospital with the new crown within 30 days and the clinical symptom assessment.
The final clinical trial results, which included data from 134 subjects in the pro cruminide treatment group and 128 subjects in the placebo control group, showed that no subjects in the pro cruminide treatment group were hospitalized at a rate of 0%, while 35 subjects in the control group deteriorated and were hospitalized at a rate of 27%.
of psyruamine significantly reduced hospitalization rates in new coronary subjects, and no adverse events associated with psyruamine were observed during the study period.
(Preliminary data from the new crown clinical trial of psyruamine therapy published by Pioneer Pharmaceuticals on December 11, 2020 showed that one of the subjects in the pyrethroide treatment group was hospitalized for informational errors and corrected.)
) Detailed final clinical trial data can be obtained from recently planned publicly available papers.
addition, clinical trials of psyrusamine for female subjects with new crowns are under way in Brazil, with a planned group of 168 subjects and preliminary data to be released in the near future. Dr. Tong You, founder, chairman and chief executive officer of
Pioneer Pharmaceuticals, said, "We are very pleased to see that procroamine has performed well in the treatment of the new crown, the recent recurrence of the outbreak in some areas, the emergence of mutant new coronavirus in many countries, accelerating the spread of the epidemic, we will accelerate the promotion of the international multi-center clinical trial of the new crown of pro cruminide treatment, as soon as possible to benefit more new crown patients."
”